EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies

Ye Yang iD, Su Fang Wu, Wei Bao

International Journal of Gynecology & Obstetrics · 2024-02 · 164 (2) · 436-459

DOI: 10.1002/ijgo.14969 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 31.07.2023. Verfasst von Ye Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Project of Shanghai Health Commission, Natural Science Foundation Shanghai Project, Shanghai Songjiang District Science and Technology Commission for Funding the Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

When determining adjuvant treatment for endometrial cancer, the decision typically relies on factors such as cancer stage, histologic grade, subtype, and a few histopathologic markers. The Cancer Genome Atlas revealed molecular subtyping of endometrial cancer, which can provide more accurate prognostic information and guide personalized treatment plans.

Objective

To summarize the expression and molecular basis of the main biomarkers of endometrial cancer. Search Strategy PubMed was searched from January 2000 to March 2023. Selection Criteria Studies evaluating molecular subtypes of endometrial cancer and implications for adjuvant treatment strategies. Data Collection and Analysis Three authors independently performed a comprehensive literature search, collected and extracted data, and assessed the methodological quality of the included studies. Main Results We summarized the molecular subtyping of endometrial cancer, including mismatch repair deficient, high microsatellite instability, polymerase epsilon (POLE) exonuclease domain mutated, TP53 gene mutation, and non‐specific molecular spectrum. We also summarized planned and ongoing clinical trials and common therapy methods in endometrial cancer. POLE mutated endometrial cancer consistently exhibits favorable patient outcomes, regardless of adjuvant therapy. Genomic similarities between p53 abnormality endometrial cancer and high‐grade serous ovarian cancer suggested possible overlapping treatment strategies. High levels of immune checkpoint molecules, such as programmed cell death 1 and programmed cell death 1 ligand 1 can counterbalance mismatch repair deficient endometrial cancer immune phenotype. Hormonal treatment is an appealing option for high‐risk non‐specific molecular spectrum endometrial cancers, which are typically endometrioid and hormone receptor positive. Combining clinical and pathologic characteristics to guide treatment decisions for patients, including concurrent radiochemotherapy, chemotherapy, inhibitor therapy, endocrine therapy, and immunotherapy, might improve the management of endometrial cancer and provide more effective treatment options for patients.

Conclusions

We have characterized the molecular subtypes of endometrial cancer and discuss their value in terms of a patient‐tailored therapy in order to prevent significant under‐ or overtreatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsFemaleHumansPoly-ADP-Ribose Binding ProteinsMutationPrognosisNeoplasm StagingBiomarkers, Tumor

Stichwörter der Autor:innen

TP53 gene mutationdefective mismatch repairendometrial cancermicrosatellite instabilitynon-specific molecular spectrumpolymerase epsilon exonuclease domain mutated

Substanzen

Poly-ADP-Ribose Binding ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Obstetrics and Gynecology Department, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.

ORCID-Profile: Ye Yang

Förderung

  • Clinical Research Project of Shanghai Health Commission
  • Natural Science Foundation Shanghai Project
  • Shanghai Songjiang District Science and Technology Commission for Funding the Project

Zitieren

APA

Yang, Y., Wu, S. F., & Bao, W. (2024). Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies. International Journal of Gynecology & Obstetrics, 164(2), 436-459. https://doi.org/10.1002/ijgo.14969

Vancouver

Yang Y, Wu SF, Bao W. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies. International Journal of Gynecology & Obstetrics. 2024;164(2):436-459. doi:10.1002/ijgo.14969

BibTeX
@article{Yang2024,
  author = {Yang, Ye and Wu, Su Fang and Bao, Wei},
  title = {Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2024},
  volume = {164},
  number = {2},
  pages = {436--459},
  doi = {10.1002/ijgo.14969}
}
Kostenlos starten →